Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)

Inclusion Criteria:

• Age ≥ 19 yrs
• Severe aortic stenosis or severe aortic regurgitation
• Agree to consent for self
• Can follow-up for the next 2 years

Exclusion Criteria:

• Pre-existing acute kidney injury
• Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy
• On ECMO or IABP
• Life expectancy < 12 months
• Pregnancy